Correction: Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical trial

Affiliations

¹ Department of Dermatology, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
² Department of Dermatology, Chinese PLA General Hospital, Beijing, China.
³ Department of Dermatology, The First Hospital of Jilin University, Changchun, China.
⁴ General Hospital of Northern Theater Command, Chinese PLA, Shenyang, China.
⁵ The First Affiliated Hospital of Air Force Medical University, Xi'an, China.
⁶ Department of Dermatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
⁷ The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
⁸ The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
⁹ Shanghai Skin Disease Hospital, Shanghai, China.
¹⁰ Department of Dermatology, Ningbo Second Hospital, Ningbo, Zhejiang, China.
¹¹ Department of Dermatology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
¹² Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
¹³ Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
¹⁴ Department of Dermatology, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. rmzjz@126.com.

Published Erratum

Lin Cai et al. Dermatol Ther (Heidelb). 2025 Oct.

. 2025 Oct;15(10):2817-2818.

doi: 10.1007/s13555-025-01480-5.

¹ Department of Dermatology, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
² Department of Dermatology, Chinese PLA General Hospital, Beijing, China.
³ Department of Dermatology, The First Hospital of Jilin University, Changchun, China.
⁴ General Hospital of Northern Theater Command, Chinese PLA, Shenyang, China.
⁵ The First Affiliated Hospital of Air Force Medical University, Xi'an, China.
⁶ Department of Dermatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
⁷ The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
⁸ The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
⁹ Shanghai Skin Disease Hospital, Shanghai, China.
¹⁰ Department of Dermatology, Ningbo Second Hospital, Ningbo, Zhejiang, China.
¹¹ Department of Dermatology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
¹² Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
¹³ Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
¹⁴ Department of Dermatology, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. rmzjz@126.com.

No abstract available

Erratum for

Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical trial.
Cai L, Li C, Li S, Zhang X, Wang G, Yu J, Huang K, Fang H, Ding Y, Wang J, Jiang C, Lu Q, Tao J, Zhang J. Cai L, et al. Dermatol Ther (Heidelb). 2025 Oct;15(10):2803-2816. doi: 10.1007/s13555-025-01450-x. Epub 2025 Jun 15. Dermatol Ther (Heidelb). 2025. PMID: 40517362 Free PMC article.